

1 **Symptoms persisting after hospitalization for COVID-19: 12 months**  
2 interim results of the COFLOW study

3

4 L.M. Bek<sup>1\*</sup>, J.C. Berentschot<sup>2\*</sup>, M.H. Heijnenbrok-Kal<sup>1,3</sup>, S. Huijts<sup>2</sup>, M.E. van Genderen<sup>4</sup>, J.H. Vlake<sup>4</sup>, J.  
5 van Bommel<sup>4</sup>, J.G.J.V. Aerts<sup>2</sup>, G.M. Ribbers<sup>1,3</sup>, H.J.G. van den Berg-Emons<sup>1\*\*</sup>, M.E. Hellemons<sup>2\*\*</sup> on  
6 behalf of the CO-FLOW collaboration Group\*\*\*

7 \* Authors share first authorship. \*\* Share senior authorship

8 \*\*\* Collaboration Group authors mentioned on last page

9

10 **Affiliations:**

11 <sup>1</sup>Department of Rehabilitation Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

12 <sup>2</sup>Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

13 <sup>3</sup>Rijnndam Rehabilitation, Rotterdam, The Netherlands.

14 <sup>4</sup>Department of Intensive Care, Erasmus Medical Center, Rotterdam, The Netherlands.

15

16

17 **Short title:** Persisting symptoms 12 months after COVID-19

18 **Correspondence:** M.E. Hellemons, Department of Respiratory Medicine, Erasmus Medical Centre, Dr.

19 Molewaterplein 40, 3015 GD Rotterdam, The Netherlands, m.hellemons@erasmusmc.nl

20

21 **ABSTRACT**

22 **Introduction:** A large proportion of patients experiences a wide range of sequelae after acute COVID-  
23 19 infection, especially after severe illness. The long-term health sequelae need to be assessed. Our  
24 objective was to longitudinally assess persistence of symptoms and clusters of symptoms up to 12  
25 months after hospitalization for COVID-19, and to assess determinants of the main persistent  
26 symptoms.

27 **Methods:** In this multicenter prospective cohort study patients with COVID-19 are followed up for 2  
28 years with measurements at 3, 6, 12, and 24 months after hospital discharge. Here, we present  
29 interim results regarding persistent symptoms up to 12 months. Symptoms were clustered into  
30 physical, respiratory, cognitive and fatigue symptoms.

31 **Results:** We included 492 patients; mean age was 60.2±10.7 years, 335 (68.1%) males, median length  
32 of hospital stay 11 (6.0-27.0) days. At 3 months after discharge 97.0% of the patients had at least 1  
33 persisting symptom, this declined to 95.5% and 92.0% at 6 and 12 months, respectively ( $p=0.010$ ).

34 Muscle weakness, exertional dyspnea, fatigue, and memory and concentration problems were the  
35 most prevalent symptoms with rates over 50% during follow-up. Over time, muscle weakness, hair  
36 loss, and exertional dyspnea decreased significantly ( $p<0.001$ ), while other symptoms, such as  
37 fatigue, concentration and memory problems, anosmia, and ageusia persisted. Symptoms from the  
38 physical and respiratory cluster declined significantly over time, in contrast to symptoms from the  
39 fatigue and cognitive clusters. Female gender was the most important predictor of persistent  
40 symptoms and co-occurrence of symptoms from all clusters. Shorter hospital stay and treatment  
41 with steroids were related with decreased muscle weakness; comorbidity and being employed were  
42 related with increased fatigue; and shorter hospital stay and comorbidity were related with memory  
43 problems.

44 **Conclusion:** The majority of patients experienced COVID-19 sequelae up to 12 months after  
45 hospitalization. Whereas physical and respiratory symptoms showed slow gradual decline, fatigue  
46 and cognitive symptoms did not evidently resolve over time. This finding stresses the importance of  
47 finding the underlying causes and effective treatments for post-COVID condition, beside adequate  
48 COVID-19 prevention.

49

50

51 **INTRODUCTION**

52 Acute coronavirus disease 2019 (COVID-19) infection in humans is associated with a heterogeneous  
53 range of symptoms including respiratory, musculoskeletal, gastrointestinal, and neurological  
54 symptoms. In 5-14% of patients the respiratory consequences of COVID-19 are severe, requiring  
55 hospitalization for oxygen supplementation or even prolonged ventilatory support (1).

56 Whereas a proportion of patients fully recovers, it becomes increasingly clear that a proportion of  
57 patients experiences a wide range of long-lasting sequelae after acute COVID-19 infection. Different  
58 terms are currently used for describing the presence of post-COVID-19 symptoms, such as long  
59 COVID, long haulers, post-COVID-19 syndrome, persistent post-COVID, and post-acute sequelae of  
60 COVID (PASC). Although several definitions are in place, persistent symptoms after COVID-19 are  
61 regarded as post-COVID-19 syndrome if they persist or present within 12 weeks of the onset of  
62 acute COVID-19 and last for at least 2 months, and are not attributable to alternative diagnoses (2,  
63 3). The more recent World Health Organization (WHO) definition of post COVID-19 condition (PCC) is  
64 very similar to this definition, adding that symptoms may be new onset following initial recovery  
65 from an acute COVID-19 episode or persist from the initial illness and must persist for at least two  
66 months (4). Symptoms may also fluctuate or relapse over time. These post-acute COVID-19 sequelae  
67 encompass a wide range of symptoms and organs systems. Common symptoms include fatigue,  
68 shortness of breath and cognitive dysfunction (3, 4).

69 Although exact overall prevalence of these long-term symptoms remains unclear, it is estimated that  
70 between 2.6% and 13.7% of symptomatic patients experience persistent symptoms beyond 12 weeks  
71 after COVID-19 infection (5, 6). This number increases when patients are more severely affected (7).  
72 A recent systematic review described that more than 50% of all patients (the majority after  
73 hospitalization) experience post-acute COVID-19 sequelae, even up to 6 months after acute infection  
74 (8). Recent data from a Chinese cohort demonstrated that symptoms were still present in over 68%  
75 of hospitalized patients at 6 months after disease onset, decreasing to 49% at 12 months (9, 10).

76 The nature of the reported symptoms is diverse and ranges from exertional dyspnea to sensory  
77 overload. Although studies have tried to phenotype the patients with residual symptoms, looked into  
78 co-occurrence of pairs of post-COVID-19 symptoms, or report on assays of symptoms according to  
79 various organ systems, it remains unclear how the various domains of symptoms relate to each other  
80 and how frequently certain types of symptoms overlap (11-13).

81

82

83 Currently, most reports on persistent symptoms remain limited to 6 months after infection and little  
84 is known regarding the determinants of persistent symptoms. Also, most studies are cross-sectional  
85 and studies reporting outcomes across multiple time-points are scarce.

86 The aim of the current study was therefore to assess persistence of symptoms up to 12 months after  
87 discharge, to evaluate how persistent symptoms and clusters of symptoms develop over time, to  
88 determine how various clusters of symptoms overlap with each other, and to assess determinants of  
89 the main persistent symptoms after COVID-19.

90

91

92

93

94

95 **METHODS**

96 Study design

97 The COvid-19 Follow-up care paths and Long-term Outcomes Within the Dutch health care system  
98 (CO-FLOW) study is an ongoing multicenter prospective cohort study following COVID-19 patients  
99 discharged from hospitals in the Rotterdam-Rijnmond-Delft region in the Netherlands. Detailed  
100 description of its protocol can be found elsewhere (14). In short, up to 2 years after hospitalization  
101 patients with COVID-19 are evaluated at 3, 6, 12, and 24 months after hospital discharge. Here, we  
102 present interim results regarding persisting symptoms obtained in the period from July 1<sup>st</sup> 2020 until  
103 December 1<sup>st</sup> 2021 as part of the CO-FLOW study up to 12 months after discharge. The Medical Ethics  
104 Committee of the Erasmus Medical Center (MC) approved this study (MEC-2020-0487). The trial was  
105 registered at The Netherlands Trial Register (NL8710), <https://www.trialregister.nl>, on June 12, 2020.

106 Adult patients ( $\geq 18$  years of age) were eligible to participate in the CO-FLOW study if they had been  
107 hospitalized for COVID-19 (diagnosis based on either positive reverse transcription polymerase chain  
108 reaction or a clinical diagnosis combined with positive serology for COVID-19) within the previous 6  
109 months and patient or relative had sufficient knowledge of the Dutch or English language.  
110 Incapacitated patients were unable to participate given the study procedures. For this study only  
111 participants with at least two study visits were included.

112

113 Study Procedures

114 Patients were recruited during outpatient follow-up after discharge in one of the participating  
115 centers, at the inpatient rehabilitation center, or at the skilled nursing facility. All patients provided  
116 written informed consent before the start of the measurements. Study visits were synchronized with  
117 the patient's regular follow-up for COVID-19 at each of the participating centers if possible. When  
118 patients were discharged from regular follow-up, study visits continued in the Erasmus University MC  
119 or, if patients were unable to come to the Erasmus University MC, a research assistant performed the  
120 study visit at home. During study visits patients performed non-invasive clinical tests, including  
121 physical, psychological, and cognitive evaluation. At 3, 6, and 12 months follow-up visits, patients  
122 received questionnaires via email or postal mail. Data were stored in Castor EDC (Castor EDC,  
123 Amsterdam, The Netherlands).

124

125 Outcomes

126 A new Corona Symptom Checklist was developed for this study on 'novel or worsened symptoms  
127 since the onset of COVID-19' during the first three months of the study, based on the first

128 experiences with post-COVID-19 patients. All questions are answered with “yes” or “no” (see  
129 appendix for complete questionnaire). During the study visits the Corona Symptom Checklist was  
130 administered by a research assistant in a face-to-face interview. As the Checklist was still under  
131 development when the study started amid the beginning of the COVID-19 pandemic, it was  
132 introduced at all study visits after August 5<sup>th</sup> 2020. As the pandemic evolved and knowledge  
133 increased regarding PCC, additional questions were added (sensory overload, headache, chest pain)  
134 from June 2021 onwards.

135 As fatigue is considered as one of the most prevalent symptoms in PCC, we chose to report fatigue  
136 not based on the checklist results, but on the validated Fatigue Assessment Scale (FAS) that was  
137 assessed in all patients since study onset. The FAS is a 10-item self-report questionnaire and is  
138 validated in patients with chronic lung disease (15). The items are scored on a Likert scale ranging 1-  
139 5. A total score of  $\geq 22$  is considered to represent substantial fatigue and was used to indicate  
140 persisting fatigue (15).

141 Patient and clinical characteristics were collected at study visits and through electronic patient  
142 records. Patients characteristics included age, sex, body mass index (BMI), migration background,  
143 pre-COVID educational and employment status, smoking status, and comorbidities. Clinical  
144 characteristics included baseline laboratory and radiological parameters, complications during  
145 hospitalization including delirium and thrombosis, type and quantity of oxygen support, intensive  
146 care unit (ICU) admission, length of stay (LOS) ICU, LOS hospital, and COVID-19 directed treatment  
147 during hospital admission.

148

#### 149 Statistical analyses

150 We examined descriptive statistics to ensure data met statistical assumptions. Variables were  
151 presented as mean with standard deviation (SD), median with interquartile range, or numbers (n)  
152 with percentages (%) as appropriate.

153 Patient reported symptoms were clustered into one of four clusters according to the nature of the  
154 symptom: physical, respiratory, fatigue, and cognitive symptom cluster. The physical symptom  
155 cluster was composed of the symptoms muscle weakness, balance problems/dizziness, joint pain,  
156 tingling/numbness in extremities, hair loss, headache, chest pain, skin rash, vision problems,  
157 hoarseness, anosmia, ageusia, stool problems, claudication, hearing problems, and miction problems.  
158 The respiratory symptom cluster was composed of the symptoms exertional dyspnea, dyspnea,  
159 cough, and phlegm. The fatigue symptom clusters was composed of fatigue and sleeping problems.  
160 The cognitive symptom cluster was composed of the symptoms memory problems, concentration  
161 problems, sensory overload, and anxiety/nightmares. If any of the symptoms in the clusters was

162 present at a time point, persisting symptoms in that cluster were scored as present at that time  
163 point. We used generalized estimating equations (GEE) with an unstructured covariance matrix to  
164 assess persistence of symptoms and symptom clusters over time. GEE accounts for correlations  
165 between patient follow-up measurements and includes all observed outcomes despite incomplete  
166 data. For longitudinal analyses, a Bonferroni correction was applied and a p-value <0.002 was  
167 considered statistically significant. Difference in the distribution of symptom clusters across gender  
168 were assessed with a Chi-Square test. Lastly, we performed multivariable logistic regression analyses  
169 with a backward selection procedure to determine which variables are independently associated  
170 with the most prevalent symptom per cluster at 3 months after discharge. The dependent variables  
171 were muscle weakness, deconditioning/exertional dyspnea, fatigue, and memory problems. We only  
172 reported determinants of symptoms at 3 months after discharge, as symptoms were most prevalent  
173 at 3 months after discharge and the majority did not decrease significantly over time. Determinants  
174 that were examined were age, sex, BMI, migration background (European, Dutch Caribbean, Asian,  
175 Turkish, and (North) African), pre-COVID educational (low, middle, high) and employment status  
176 (employed, not employed, retired), presence of comorbidity, smoking (never versus ever), BMI and  
177 C-reactive protein (CRP) at admission, complications of thrombosis or delirium, oxygen  
178 supplementation (none, nasal cannula or mask oxygen supplementation, high flow nasal cannula,  
179 mechanical ventilation), LOS hospital, and COVID-19 directed treatment with steroids. The covariates  
180 BMI and CRP were imputed with their mean value if missing. Variable elimination from the  
181 multivariable models was based on goodness of fit using the likelihood ratio test with a p-value of  
182 0.1, and the final models are presented with adjusted odds ratios (OR) and 95% confidence interval  
183 (95%CI). All analyses were performed using Statistical Package for Social Sciences (SPSS) version 25  
184 (IBM SPSS statistics, SPSS Inc, Chicago, IL, USA) and STATA version 8SE (StataCorp LLC, Texas, USA)  
185 and R version 4.1.1 (R-Foundation) were used for graphs.

186

187

## 188 RESULTS

### 189 Characteristics

190 Between July 1<sup>st</sup> 2020 and December 1<sup>st</sup> 2021, a total of 650 patients were included in COFLOW, of  
191 whom 492 participants underwent at least two study measurements and were included in this  
192 interim analysis. Baseline characteristics are presented in table 1. Patients had a mean age of  
193 60.2±10.7 years, 335 (68.1%) were male, 403 (81.9%) had one or more comorbidities: most  
194 commonly obesity, cardiovascular, or pulmonary disease. Oxygen supplementation during admission  
195 was required by 474 (96.3%) patients, 199 (40.4%) had been admitted to the ICU, with a median LOS  
196 in ICU of 17 (9.0-30.5) days, and the median total LOS in the hospital was 11 (6.0-27.0) days. Of all  
197 patients, 357 (72.6%) received any COVID-19 directed treatment, of whom 330 (70.8%) received any  
198 form of steroids and 54 (11.5%) received directed anti-inflammatory treatment.

199 In total, 492 participant underwent at least two study measurements with the symptoms checklist.  
200 The flowchart of the included patients and study measurements is shown in figure 1.

201

### 202 Persisting symptoms

203 Table 2 presents the number and proportion of patients with persisting symptoms at each follow-up  
204 measurement. At 3 months after discharge, 97.0% of the patients had at least 1 persisting symptom,  
205 this proportion of patients declined to 95.5% at 6 months and to 92.0% at 12 months ( $p=0.010$ ).  
206 Presence of a single symptom varied from 9.7% for miction problems to 81.8% for exertional  
207 dyspnea. At all study visits, the most prevalent symptoms were muscle weakness, exertional  
208 dyspnea, fatigue, and memory and concentration problems. These symptoms were reported by more  
209 than 50% of the patients during follow-up; a large number of other persistent symptoms was  
210 frequently reported, presented in table 2 and figure 2. Symptoms that significantly declined over  
211 time were muscle weakness, hair loss, and exertional dyspnea ( $p<0.001$ ).

212

### 213 Symptom clusters

214 The prevalence of symptoms and the overlap between symptom clusters at 3 months follow-up is  
215 shown in figure 2. At 3 months, 90.7% of patients reported at least 1 symptom from the physical  
216 symptom cluster; this declined significantly to 86.8% at 6 months and to 84.5% at 12 months  
217 ( $p=0.025$ ). Respiratory symptoms were reported by 87.3%, 79.1%, and 76.0% of the patients at 3, 6,  
218 and 12 months, respectively ( $p<0.001$ ). In the fatigue symptom cluster, 68.3% of the patients



219 reported a symptom at 3 months, 67.8% at 6 months, and 67.6% at 12 months ( $p=0.082$ ). A symptom  
220 from the cognitive symptom cluster was reported in 71.8% of the patients at 3 months, 70.0% at 6  
221 months, and 74.2% at 12 months ( $p=0.452$ ).

222 At 3 months after hospital discharge, 218 (56.3%) reported symptoms in all 4 symptoms clusters and  
223 292 (75.5%) in 3 clusters. Symptoms in the physical and respiratory symptom clusters most  
224 frequently overlapped (figure 3A). The majority of patients with fatigue also experience cognitive  
225 symptoms (86.8%), and vice versa (83.4%). Isolated symptoms were rare, but concerned most  
226 frequently fatigue in 21 (5.3%) patients or physical symptoms in 18 (4.6%) patients. Females more  
227 frequently report symptoms in all four clusters than males (63% versus 52%,  $p<0.001$ ) (figure 3B and  
228 3C). Fatigue and cognitive symptoms were more frequent in female than in males (80.2% versus  
229 68.6%,  $p=0.002$ ), and 74.5% versus 68.6%,  $p=0.009$ , respectively), and so were the frequency of  
230 respiratory (85.9% versus 85.5%,  $p=0.022$ ) and physical symptoms (90% versus 88.5%,  $p=0.002$ ).

231 In table 3 patient and clinical characteristics of patients hospitalized for COVID-19 at three months  
232 follow-up are presented across the number of symptoms clusters affected. The majority of patients  
233 (89%) experiences symptoms in 2 or more clusters. Several trends can be noticed in with increasing  
234 number of symptoms clusters affected; more in females, patients with non-European background,  
235 employment, co-morbidities and with lower CRP, lower D-dimer and more severely affected chest X-  
236 ray upon admission. No association seems present with LOS, ICU admission and ventilation and with  
237 COVID-19 directed treatment. As numbers per group/characteristic were limited, differences were  
238 not statistically assessed and these trends should be considered as explorative and hypotheses  
239 generating.

240

#### 241 Determinants of persisting symptoms

242 Out of the physical symptom cluster, muscle weakness was the most frequently reported symptom  
243 at 3 months after hospital discharge. Patients who were female (OR(95%CI):2.66 (1.62, 4.37),  
244  $p<0.001$ ), had a longer LOS hospital (1.04 (1.02, 1.05),  $p<0.001$ ) were more likely to experience  
245 muscle weakness at 3 months after hospital discharge and patients who received steroids as  
246 treatment during hospitalization (0.53 (0.29, 0.96),  $p=0.036$ ) were less likely to experience muscle  
247 weakness (figure 4). Out of the respiratory symptom cluster, exertional dyspnea was the most  
248 prevalent symptom. We were unable to perform valid multivariable logistic regression on this  
249 outcome given the high prevalence of this symptom (81.5%) at 3 months after hospital discharge.

250 Fatigue was the most prevalent symptom in the fatigue symptom cluster. Patients who were female  
251 (2.76 (1.61, 4.76),  $p<0.001$ ) and/or had comorbidities (2.19 (1.24, 3.87),  $p=0.007$ ) were more likely to

252 develop fatigue symptoms, while patients who were retired (0.38 (0.22, 0.65), p=0.001) were less  
253 likely to develop fatigue symptoms at 3 months after hospital discharge (figure 4).  
254 At 3 months, memory problems was the most frequently reported symptom in the cognitive  
255 symptom cluster. Patients who were female (2.01 (1.30, 3.39), p=0.002), had a shorter length of stay  
256 (0.98 (0.97, 0.99), p=0.003), and/or had comorbidities (1.95 (1.12, 3.40), p=0.018) were more likely to  
257 experience memory problems at 3 months after hospital discharge (figure 4).

## 258 **DISCUSSION**

259 Up to 12 months after hospitalization for COVID-19 over 90% of patients suffer from at least 1  
260 persisting symptom. Muscle weakness, exertional dyspnea, fatigue, and memory and concentration  
261 problems were the most prevalent symptoms with reporting rates over 50% of the patients at one of  
262 the time points. Although several physical and respiratory symptoms (muscle weakness, hair loss,  
263 exertional dyspnea) declined significantly over time, others - including fatigue and cognitive  
264 symptoms - persisted.

265 Our findings support the observation from a recent meta-analysis describing that the short-term  
266 prevalence of persisting symptoms were similar to long-term prevalence of symptoms, up to six  
267 months after hospital discharge (8). Persisting symptoms are a common feature of COVID-19,  
268 especially after hospitalization. To date, long-term data regarding persisting symptoms at 12 months  
269 and beyond are limited. In a cohort study from Wuhan, the proportion of persistent symptoms was  
270 shown to decrease from 68% at 6 months to 49% at 12 months after hospitalization (10). Although  
271 this finding appears to contrast our findings, their cohort contained only 1% of patients that had  
272 received mechanical ventilation compared to 35.6% in our cohort. The severity of the acute COVID-  
273 19 infection is increasingly recognized to be associated with a larger proportion, and longer duration  
274 of persisting symptoms and should thus be taken into account when comparing studies (16, 17). Our  
275 study unfortunately shows a much less optimistic picture regarding recovery over time, with high  
276 prevalence of persisting symptoms. More and longer term follow-up results will be collected to  
277 obtain even more insight into the future outlook of these patients.

278 Looking into determinants, female gender was the most important predictor of persistent symptoms.  
279 Earlier, we have demonstrated a relation of female gender with increased risk for fatigue up to six  
280 months after discharge (7). Now we extend these findings to other symptoms and show that females  
281 more frequently experience symptoms from multiple symptom clusters 3 months after  
282 hospitalization. Previous studies have also demonstrated that female gender was associated with an  
283 increased number of persisting symptoms (10, 18). It is frequently stated that, while acute cases of  
284 COVID-19 tend to be most severe in older males, PCC seems to be more frequent in younger females.  
285 Age however, was not found to be a determinant of persistent symptoms in our cohort, neither in  
286 other studies after adjustment for confounders (10, 18). Also, it is necessary to bear in mind that  
287 there may be a bias in symptoms reporting between males and females (19). We also found presence  
288 of comorbidity to be associated with increased fatigue and memory problems, but this was not found  
289 by others (10). It is well possible that pre-existent health problems make patients more vulnerable  
290 for unfavorable outcome after severe illness.

291 Although numbers of acute COVID-19 may eventually decrease with increasing immunity in the  
292 population, our findings point out that consequences will be long felt by many. As challenges in

293 vaccination programs worldwide continue to hinder effective control measures, the number of  
294 people with PCC will only continue to increase. Vaccination may play an important role not only to  
295 prevent new infections, but also in preventing PCC, as it was recently demonstrated that post-  
296 vaccination breakthrough infections are less likely to be associated with symptoms persisting for  
297 more than 28 days (20).

298 The best approach to PCC is unclear. As symptoms range from mild to severe and are very diverse in  
299 nature, there is no one size fits all treatment possible. Although we grouped symptoms into clusters,  
300 there are currently no universal recognized phenotypes, diagnostic criteria, minimal severity scores,  
301 or a diagnostic test to establish a diagnosis of PCC. Establishing more objective and evidence-based  
302 definitions and phenotypes of PCC will be necessary to compare findings across cohorts and settings,  
303 and to establish evidence based interventions. Also, the impact of prior symptoms and prior  
304 comorbidity need to be taken into account, just as the expected effects of hospitalization.

305 There are currently many unknowns regarding PCC, including the underlying mechanisms. Current  
306 theories on PCC include virus-specific pathophysiologic changes, immunologic aberrations and  
307 inflammatory damage in response to the acute infection, and expected sequelae of post-  
308 critical illness (21). Indeed, it is very hard to differentiate between the expected sequelae, such as  
309 described in the post-intensive care syndrome, and the sequelae that are specific for COVID-19 (22).  
310 Nonetheless, in a large analysis on electronic health records data, key features of long-COVID (e.g.  
311 breathlessness and fatigue) were more frequently reported after COVID-19 infection than in matched  
312 controls after Influenza infection (13). Overall, it is becoming increasingly clear that the sequelae  
313 after COVID-19 are more prevalent than after most other types of infections, persist for a long time,  
314 and have a major impact on the burden of disease and health care.

315 Our study has several strengths and limitations. We followed a large cohort of patients in a  
316 longitudinal design at 3, 6, and 12 months after hospital discharge. Currently, long-term follow-up  
317 data are scarce. As the study is still ongoing, data were not complete for the entire cohort; also, the  
318 initial patients were generally recruited between 3 and 6 months after hospital discharge, resulting in  
319 unequal groups at different time points. We therefore included only participants with data of at least  
320 two study measurements, and used GEE models to make maximal use of all data and to investigate  
321 how symptoms developed over time.

322 One inclusion criterium was that patients or their relatives had to be able to communicate in Dutch  
323 or English. Therefore, there is underrepresentation of individuals with a migration background in this  
324 study compared to the community where this cohort was established. Nonetheless, 24% of the  
325 participants in this cohort had a migration background; migration background was not a predictor of  
326 residual symptoms in this study. Another limitation is that our results are only generalizable to

327 hospitalized patients. Also, we did not have patient scores on the severity of complaints. Even though  
328 symptoms may persist for considerable time, the severity may very well decrease over time, as was  
329 also shown in other studies (16).

330 To summarize, a large number of post COVID-19 patients experienced persistent symptoms up to 12  
331 months after hospitalization for COVID-19. Whereas physical and respiratory symptoms show slow  
332 gradual decline, fatigue and cognitive symptoms did not evidently resolve over time. This finding  
333 stresses the importance of finding the underlying causes and effective treatments for PCC on the one  
334 hand, and adequate COVID-19 prevention on the other hand. Large and long-term cohort studies  
335 together with broader consortia are urgently needed to help better understand the trajectory,  
336 complications, and biological mechanisms that drive persistent symptoms after COVID-19 infection.

337

338

339

340

341 **Table 1** Patient and clinical characteristics of patients hospitalized for COVID-19

	n	All (N=492)
<b>Patient characteristic</b>		
Age, years		60.2 ± 10.7
Sex, male		335 (68.1)
BMI, kg/m <sup>2</sup>	437	29.3 ± 5.5
<i>Migration Background</i>	491	
European		373 (76.0)
Dutch Caribbean		61 (12.4)
Asian		25 (5.1)
Turkish		18 (3.7)
(North) African		14 (2.9)
<i>Pre-COVID education</i>	489	
Low		166 (33.9)
Middle		172 (35.2)
High		151 (30.9)
<i>Pre-COVID employment</i>	490	
Unemployed		77 (15.7)
Employed		297 (60.6)
Retired		116 (23.7)
<i>Smoking status</i>	491	
Never		211 (43.0)
Former		270 (55.0)
Current		10 (2.0)
<i>Comorbidities</i>		
≥1		403 (81.9)
Obesity (BMI≥30)		190 (38.6)
Diabetes		95 (19.3)
Cardiovascular disease/ hypertension		192 (39.0)
Pulmonary disease		119 (24.2)
Renal disease		46 (9.3)
Gastrointestinal disease		22 (4.5)
Neuromuscular disease		49 (10.0)
Malignancy		56 (11.4)
Autoimmune/inflammatory disease		54 (11.0)
Mental disorder		25 (5.1)
<b>In-hospital characteristics</b>		
PCR confirmed SARS-CoV-2		485 (98.6)
Serology confirmed SARS-CoV-2		7 (1.4)
<i>Laboratory values</i>		
Creatinine, umol/L	471	82.0 (69.0-100.0)
(CKD-EPI) eGFR, ml/min	456	82.0 (66.0-90.0)
CRP, mg/L	467	85.0 (47.0-154.0)

Ferritin, ug/L	284	832.5 (443.5-1613.3)
ALAT, U/L	457	37.0 (26.0-56.0)
Hemoglobin, mmol/L	468	8.6 (7.9-9.2)
MCV, fl	461	89.0 (85.0-91.0)
Trombocyten, 10 <sup>9</sup> /L	463	211.0 (159.0-276.0)
Lymphocytes absolute count, 10 <sup>9</sup> /L	325	0.9 (0.6-1.1)
D-dimer, mg/L	237	1.1 (0.6-380.0)
NT-pro-BNP, pmol/ml	90	18.5 (8.8-48.0)
IL-6, pmol/ml	36	55.5 (28.0-179.0)
<i>Chest x-ray abnormalities</i>	468	
Normal		59 (12.6)
Moderate		99 (21.2)
Severe		310 (66.2)
Thrombosis	484	79 (16.3)
Delirium	477	121 (25.4)
Requiring oxygen supplementation	492	474 (96.3)
Requiring high flow nasal cannula	462	150 (32.5)
ICU admission		199 (40.4)
Invasive mechanical ventilation		175 (35.6)
Length of intubation, days	167	14.0 (8.0-27.0)
Tracheostomy	482	64 (13.3)
Length of ICU stay, days	197	17.0 (9.0-30.5)
Length of hospital stay, days		11.0 (6.0-27.0)
<i>COVID-19 directed Treatment</i>	466	
None		109 (23.4)
(Hydroxy)chloroquine		14 (3.0)
Steroids		330 (70.8)
Antivirals		69 (14.8)
Anti-inflammatory (IL-6) treatment		54 (11.6)
Convalescent plasma		8 (1.7)
Monoclonal antibodies		0 (0.0)
<b>Time interval between discharge and follow-up visit</b>		
3 Months visit, days	385	94.7 ± 22.8
6 Months visit, days	483	184.8 ± 27.9
12 Months visit, days	271	368.3 ± 17.3

342

343 Data are presented as n (%), mean ± standard deviation, or, for non-normally distributed variables,  
 344 median (interquartile range). □ Adjusted n is presented for variables with a total number of patients  
 345 less than 492. BMI, Body Mass Index; IL-6, interleukin 6; PCR, Polymerase Chain Reaction, SARS-CoV-  
 346 2, Severe Acute Respiratory Syndrome coronavirus 2; ICU, Intensive Care Unit.

347

348

349 **Table 2** Prevalence of COVID-19 related symptoms at 3, 6, and 12 months follow-up in patients after  
 350 hospitalization for COVID-19

	3 Months (n=385) n (%)	6 Months (n=483) n (%)	12 Months (n=271) n (%)	p-value*
<b>Physical symptoms</b>				
Muscle weakness	220 (57.1)	234 (48.4)	111 (41.0)	<b>&lt;0.001</b>
Balance problems/dizziness	169 (43.8)	213 (44.4)	116 (42.8)	0.922
Joint pain	166 (43.2)	201 (41.6)	111 (41.0)	0.352
Tingling/numbness in extremities	147 (36.8)	163 (33.9)	86 (32.1)	0.291
Hair loss	138 (35.9)	98 (20.3)	35 (12.9)	<b>&lt;0.001</b>
Headache*	33 (31.4)	57 (26.1)	29 (18.6)	0.579
Chest pain*	29 (29.0)	40 (18.4)	28 (17.8)	0.069
Skin rash	99 (25.7)	132 (27.4)	82 (30.3)	0.587
Vision problems	97 (25.2)	148 (30.6)	78 (28.8)	0.023
Hoarseness	91 (23.6)	125 (25.9)	57 (21.0)	0.088
Anosmia	84 (21.9)	93 (19.3)	53 (19.6)	0.369
Ageusia	82 (21.2)	94 (19.5)	52 (19.2)	0.185
Stool problems	68 (17.7)	89 (18.5)	41 (15.1)	0.547
Claudication	54 (14.1)	68 (14.1)	27 (10.0)	0.116
Hearing problems	52 (13.5)	70 (14.5)	53 (19.6)	0.059
Miction problems	37 (9.7)	58 (12.1)	34 (12.5)	0.269
<b>Respiratory symptoms</b>				
Exertional dyspnea	315 (81.8)	345 (71.4)	171 (63.1)	<b>&lt;0.001</b>
Dyspnea*	78 (66.1)	114 (51.8)	83 (52.9)	0.003
Cough	112 (29.0)	119 (24.7)	66 (24.4)	0.329
Phlegm	98 (25.5)	117 (24.2)	67 (24.7)	0.727
<b>Fatigue symptoms</b>				
Fatigue	243 (64.5)	277 (63.1)	156 (60.2)	0.932
Sleeping problems	141 (36.5)	172 (35.6)	96 (35.4)	0.777
<b>Cognitive symptoms</b>				
Memory problems	211 (54.7)	271 (56.1)	158 (58.3)	0.144
Concentration problems	206 (53.4)	249 (51.6)	140 (51.7)	0.826
Sensory overload*	44 (45.5)	93 (43.9)	58 (36.7)	0.503
Anxiety/nightmares	56 (14.5)	72 (14.9)	40 (14.8)	0.785

351 \*Symptoms headache, chest pain, dyspnea, and sensory overload were added in a later stage,  
 352 resulting in lower total numbers. Data are presented as n (%) indicating the number of patients with  
 353 symptoms. p-values are based on Generalized Estimating Equation analyses, with follow-up visit as  
 354 fixed factor and symptom (yes/no) at each follow-up visit as dependent variable. Bonferroni  
 355 correction was applied for multiple testing, a p-value < 0.002 was considered statistically significant  
 356 (printed in bold).

357



**Table 3** Patient and clinical characteristics of patients hospitalized for COVID-19 divided by the number of symptoms clusters affected.

<b>Patient characteristic</b>	0 cluster (n=12)	1 cluster (n=28)	2 clusters (n=55)	3 clusters (n=74)	4 clusters (n=218)
Age, years	65.4 ± 11.8	63.0 ± 10.7	58.7 ± 11.6	61.7 ± 11.9	59.5 ± 9.8
Sex, male	12 (100.0)	23 (82.1)	44 (80.0)	54 (73.0)	141 (64.7)
BMI, kg/m <sup>2</sup>	26.6 ± 4.0	27.7 ± 4.6	29.8 ± 5.4	29.1 ± 5.2	29.9 ± 5.8
<i>Migration Background</i>					
European	11 (91.7)	23 (82.1)	41 (74.5)	56 (75.7)	164 (75.2)
Dutch Caribbean	0 (0.0)	2 (7.1)	10 (18.2)	7 (9.5)	28 (12.8)
Asian	0 (0.0)	1 (3.6)	1 (1.8)	9 (12.2)	11 (5.0)
Turkish	0 (0.0)	0 (0.0)	3 (5.5)	2 (2.7)	8 (3.7)
(North) African	1 (8.3)	2 (7.1)	0 (0.0)	0 (0.0)	7 (3.2)
<i>Pre-COVID education</i>					
Low	4 (33.3)	8 (28.6)	18 (32.7)	29 (39.7)	73 (33.6)
Middle	5 (41.7)	11 (39.3)	18 (32.7)	21 (28.8)	81 (37.3)
High	3 (25.0)	9 (32.1)	19 (34.5)	23 (31.5)	63 (29.0)
<i>Pre-COVID employment</i>					
Unemployed	1 (8.3)	3 (10.7)	12 (21.8)	12 (16.4)	35 (16.1)
Employed	5 (41.7)	17 (60.7)	28 (50.9)	40 (54.8)	146 (67.0)
Retired	6 (50.0)	8 (28.6)	15 (27.3)	21 (28.8)	37 (17.0)
<i>Smoking status</i>					
Never	4 (33.3)	14 (50.0)	24 (43.6)	24 (32.4)	89 (40.8)
Former	8 (66.7)	14 (50.0)	30 (54.5)	50 (67.6)	123 (56.4)
Current	0 (0.0)	0 (0.0)	1 (1.8)	0 (0.0)	6 (2.8)
<i>Comorbidities</i>					
≥1	7 (58.3)	19 (67.9)	45 (81.8)	62 (83.8)	186 (85.3)
Obesity (BMI≥30)	2 (16.7)	7 (25.0)	22 (40.0)	31 (41.9)	84 (38.5)
Diabetes	2 (16.7)	6 (21.4)	12 (21.8)	12 (16.2)	46 (21.1)
Cardiovascular disease/ hypertension	3 (25.0)	10 (35.7)	17 (30.9)	35 (47.3)	88 (40.4)
Pulmonary disease	2 (16.7)	3 (10.7)	13 (23.6)	14 (18.9)	69 (31.7)
Renal disease	0 (100.0)	2 (7.1)	6 (10.9)	11 (14.9)	18 (8.3)
Gastrointestinal disease	0 (100.0)	0 (100.0)	3 (5.5)	3 (4.1)	7 (3.2)


Neuromuscular disease	1 (8.3)	3 (10.7)	5 (9.1)	7 (9.5)	19 (8.7)
Malignancy	1 (8.3)	4 (14.3)	4 (7.3)	16 (21.6)	22 (10.1)
Autoimmune/inflammatory disease	1 (8.3)	4 (14.3)	4 (7.3)	7 (9.5)	27 (12.4)
Mental disorder	0 (100.0)	3 (10.7)	2 (3.6)	3 (4.1)	13 (6.0)
<b>In-hospital characteristics</b>					
PCR confirmed SARS-CoV-2	12 (100.0)	28 (100.0)	55 (100.0)	73 (100.0)	215 (98.6)
Serology confirmed SARS-CoV-2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (1.8)
<i>Laboratory values</i>					
Creatinine, umol/L	75.0 (68.0-88.8)	83.0 (75.0-91.0)	86.0 (75.0-104.8)	84.0 (70.0-107.0)	82.0 (68.3-100.0)
(CKD-EPI) eGFR, ml/min	89.0 (76.3-90.0)	82.5 (71.3-90.0)	84.0 (59.5-90.0)	78.0 (61.0-90.0)	81.5 (66.0-90.0)
CRP, mg/L	143.0 (54.8-160.0)	112.0 (55.0-190.0)	109.0 (50.0-164.0)	81.5 (50.3-148.8)	85.0 (45.0-153.5)
Ferritin, ug/L	870.5 (686.8-1186.3)	1456.5 (411.3-2054.8)	1339.0 (515.3-1900.3)	980.0 (539.3-2410.5)	832.5 (435.5-1447.3)
ALAT, U/L	38.5 (21.8-43.8)	29.0 (20.0-56.0)	39.0 (29.5-53.0)	38.5 (24.8-62.3)	36.0 (26.0-58.0)
Hemoglobin, mmol/L	8.7 (8.3-9.2)	8.8 (8.0-9.8)	9.0 (7.9-9.3)	8.6 (7.7-9.2)	8.6 (8.0-9.2)
MCV, fl	90.0 (88.0-92.0)	88.0 (87.0-92.0)	88.0 (85.0-90.3)	88.0 (84.3-92.0)	88.0 (85.0-91.0)
Trombocytin, 10 <sup>9</sup> /L	289.0 (212.0-337.0)	199.5 (158.0-257.3)	218.0 (174.0-269.0)	191.0 (143.0-297.0)	216.0 (160.0-276.5)
Lymphocytes absolute count, 10 <sup>9</sup> /L	0.6 (0.5-1.0)	0.8 (0.6-1.2)	0.9 (0.6-1.1)	0.8 (0.5-1.0)	0.9 (0.6-1.1)
D-dimer, mg/L	929.0 (2.9-1522.0)	863.0 (420.0-2802.0)	1.2 (0.7-415.3)	1.0 (0.6-7.9)	1.2 (0.6-509.8)
NT-pro-BNP, pmol/ml	44.0 (18.0-na)	18.0 (5.0-na)	23.0 (7.5-42.0)	35.5 (19.3-77.3)	16.0 (7.0-42.0)
IL-6, pmol/ml	-	-	44.0 (32.0-83.8)	280.0 (52.5-614.5)	34.0 (26.0-191.0)
<i>Chest x-ray abnormalities</i>					
Normal	2 (16.7)	3 (10.7)	6 (11.3)	8 (11.4)	26 (12.7)
Moderate	4 (33.3)	6 (21.4)	10 (18.9)	17 (24.3)	45 (22.0)
Severe	6 (50.0)	19 (67.9)	37 (69.8)	45 (64.3)	134 (65.4)
Thrombosis	3 (25.0)	4 (14.3)	9 (16.4)	12 (16.7)	33 (15.4)
Delirium	1 (8.3)	5 (17.9)	19 (35.2)	22 (31.0)	45 (21.1)
Requiring oxygen supplementation	12 (100.0)	27 (96.4)	52 (94.5)	72 (97.3)	215 (98.6)
Requiring high flow nasal cannula	0 (0.0)	8 (28.6)	27 (50.9)	23 (32.4)	71 (34.1)
ICU admission	2 (16.7)	8 (28.6)	26 (47.3)	37 (50.0)	78 (35.8)
Invasive mechanical ventilation	2 (16.7)	6 (21.4)	22 (40.0)	35 (47.3)	69 (31.7)
Length of intubation, days	7.0 (3.0-na)	28.0 (11.0-30.0)	14.0 (8.5-23.5)	17.0 (7.0-32.0)	13.0 (7.8-23.0)
Tracheostomy	0 (0.0)	2 (7.4)	9 (16.4)	15 (21.1)	18 (8.3)
Length of ICU stay, days	10.0 (5.0-na)	17.0 (2.0-31.0)	16.0 (9.0-36.8)	22.0 (10.5-35.0)	14.0 (8.0-26.5)
Length of hospital stay, days	5.0 (2.3-8.5)	11.0 (4.3-22.0)	12.0 (6.0-31.0)	15.0 (7.0-39.0)	10.0 (5.0-23.0)

<i>COVID-19 directed Treatment</i>					
None	0 (0.0)	2 (8.0)	6 (11.5)	10 (14.7)	22 (10.3)
(Hydroxy)chloroquine	0 (0.0)	1 (4.0)	1 (1.9)	0 (0.0)	3 (1.4)
Steroids	11 (100.0)	21 (84.0)	44 (84.6)	57 (83.8)	181 (85.0)
Antivirals	1 (9.1)	3 (12.0)	10 (19.2)	12 (17.6)	35 (16.4)
Anti-inflammatory treatment	0 (0.0)	2 (8.0)	6 (11.5)	11 (16.2)	30 (14.1)
Convalescent plasma	0 (0.0)	0 (0.0)	3 (5.8)	1 (1.5)	2 (0.9)
Monoclonal antibodies	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<b>Time interval between discharge and follow-up visit</b>					
3 Months visit, days	91.4 ± 21.6	97.0 ± 12.2	95.3 ± 13.9	95.4 ± 21.5	94.2 ± 26.0
6 Months visit, days	186.8 ± 7.2	183.2 ± 10.3	191.4 ± 18.0	182.4 ± 47.0	184.4 ± 28.1
12 Months visit, days	358.3 ± 19.6	366.6 ± 10.6	365.7 ± 6.6	371.4 ± 22.8	369.3 ± 22.6

Data are presented as n (%), mean ± standard deviation, or, for non-normally distributed variables, median (interquartile range). Outcomes are stratified divided by the number of symptoms clusters affected (the four symptoms clusters comprise physical, respiratory, cognitive and fatigue symptoms).

▣ Adjusted n is presented for variables with a total number of patients less than 408. BMI, body mass index; PCR, Polymerase Chain Reaction, SARS-CoV-2, Severe Acute Respiratory Syndrome coronavirus 2; ICU, Intensive Care Unit; na, not applicable.

**Figure 1:** Flowchart of the patients in the CO-FLOW study during the interim analysis



**Figure 2: Symptom prevalence over time**




Figure legend: Prevalence of COVID-19-related symptoms at 3, 6, and 12 months follow-up in patients after hospitalization for COVID-19, sorted by symptoms cluster and from most to least frequently reported. Data are presented percentage of patients with symptoms. Symptoms marked with ◊ declined significantly over time based on Generalized Estimating Equation analyses, with follow-up visit as fixed factor and symptom (yes/no) at each follow-up visit as dependent variable.

**Figure 3:** Venn Diagrams showing overlap between the symptom clusters (physical symptoms, cognitive symptoms, fatigue symptoms and respiratory symptoms) for the entire cohort (A) and for males (B), and females (C).





Figure legend: Data are presented as n (%) indicating the number of patients with symptoms.

**Figure 4.** Forest Plot of the patient and admission characteristics associated with the most prevalent symptoms for the physical, fatigue and cognitive symptoms clusters obtained by multivariable logistic regression analyses



## Appendix 1

### Corona Symptom Checklist

The following complaints may be experienced after COVID-19 infection. Check for each question whether you experienced the complaint at this moment **and** is new since the COVID-19 infection. When you experienced the complaints already before the infection and this did not change, please check “no”. When the complaints *worsened* or is *new* after infection, please check “yes”.

Complaint:	Yes	No
Do you experience a reduced vision?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced hearing?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced taste?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced smell?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience coughing problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience phlegm?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced voice?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience balance problems or dizziness?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience stool problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience miction problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience fatigue?*	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience dyspnea?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience joint complaints?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience muscle weakness?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience reduced fitness?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience hair loss?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience skin rash?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience claudication?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience sensory overload?*	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience concentration problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience memory problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience headache?*	<input type="checkbox"/>	<input type="checkbox"/>



Do you experience sleeping problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience anxiety/nightmares?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience tingling and or pain in extremities?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience chest pain?*	<input type="checkbox"/>	<input type="checkbox"/>

---

\*These questions were added from June 2021 onwards

## References

1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). *JAMA*. 2020;324(8):782.
2. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ*. 2020:m3026.
3. Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. *BMJ*. 2021:n136.
4. WHO. [Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1>
5. Sudre CH, Murray BA-OX, Varsavsky T, Graham MA-O, Penfold RS, Bowyer RA-O, et al. Attributes and predictors of long COVID. (1546-170X (Electronic)).
6. Ayoubkhani D. Statistical bulletin Office for National Statistics Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 Estimates of the prevalence of self-reported "long COVID", and the duration of ongoing symptoms following confirmed coronavirus infection, using UK Coronavirus (COVID-19) Infection Survey April 2021 [Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021>
7. Hellemons ME, Huijts S, Bek L, Berentschot J, Nakshbandi G, Schurink CAM, et al. Persistent Health Problems beyond Pulmonary Recovery up to 6 Months after Hospitalization for SARS-CoV-2; A Longitudinal Study of Respiratory, Physical and Psychological Outcomes. *Annals of the American Thoracic Society*. 2021.
8. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. *JAMA Network Open*. 2021;4(10):e2128568-e.
9. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet*. 2021;397(10270):220-32.
10. Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. *The Lancet*. 2021;398(10302):747-58.
11. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'Em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019.
12. Estiri H, Strasser ZH, Brat GA, Semenov YR, Aaron JR, Agapito G, et al. Evolving phenotypes of non-hospitalized patients that indicate long COVID. *BMC Medicine*. 2021;19(1).
13. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLOS Medicine*. 2021;18(9):e1003773.
14. Bek LM, Berentschot JC, Hellemons ME, Huijts SM, Aerts J, van Bommel J, et al. CO-FLOW: COvid-19 Follow-up care paths and Long-term Outcomes Within the Dutch health care system: study protocol of a multicenter prospective cohort study following patients 2 years after hospital discharge. *BMC Health Serv Res*. 2021;21(1):847.
15. De Kleijn WPE, De Vries J, Wijnen PAHM, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. *Respiratory Medicine*. 2011;105(9):1388-95.
16. Wynberg E, van Willigen H, Dijkstra M, Boyd A, Kootstra NA, van den Aardweg JG, et al. Evolution of COVID-19 symptoms during the first 9 months after illness onset. *medRxiv*. 2021:2021.05.05.21256710.
17. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA Network Open*. 2021;4(2):e210830.
18. Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. Long COVID in a prospective cohort of home-isolated patients. *Nature Medicine*. 2021;27(9):1607-13.

19. Bardel A, Wallander MA, Wallman T, Rosengren A, Johansson S, Eriksson H, et al. Age and sex related self-reported symptoms in a general population across 30 years: Patterns of reporting and secular trend. *PLoS One*. 2019;14(2):e0211532.
20. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *The Lancet Infectious Diseases*. 2021.
21. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, Mcgroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. *Nature Medicine*. 2021;27(4):601-15.
22. Kress JP, Hall JB. ICU-Acquired Weakness and Recovery from Critical Illness. *New England Journal of Medicine*. 2014;370(17):1626-35.

## **Acknowledgements**

We would like to extend our gratitude to all the participants of the ongoing CO-FLOW study for their efforts, as well as all the entire group of measurement-assistants that currently assists in CO-FLOW: G.W.M. Broeren, R.M.B. Imkamp, J. Andela, L. Bierman, T. Huijboom, A. Luijckx, S. Roovers, I. Simons, and L. van Veggel

## **Funding**

The study is funded by the COVID-19 Program Care and Prevention of The Netherlands Organization for Health Research and Development (ZonMw, grant number 10430022010026), and Rijndam Rehabilitation and Laurens (both in Rotterdam, The Netherlands). The review committee COVID-19 of the funding body has independently reviewed the study protocol. None of the funders have a role in the study design, nor are involved in analysis and interpretation of data or writing of the manuscript.

## **Author Contributions**

LB, JB, MHK, HB, MH devised the main conceptual ideas and proof outline for this manuscript; LB, JB, MH included the patients; LB, JB contributed to data collection and aggregation; MH and JV designed the figures; LB, JB, MHK performed the statistical analyses; LB, JB, MHK, HB, MH wrote the manuscript. All authors were involved in the main study design, discussed the results, commented on the manuscript and approved the final manuscript.

## **Authors of the CO-FLOW collaboration Group**

### **CO-FLOW collaboration Group**

Michel E. van Genderen<sup>1</sup> Jasper van Bommel<sup>1</sup>, Diederik A.M.P.J. Gommers<sup>1</sup>, Erwin Ista<sup>2,3</sup>, Robert van der Stoep<sup>4</sup>, Rutger Osterthun<sup>5,6</sup>, Markus P.J.M. Wijffels<sup>6</sup>, Marieke M. Visser<sup>6</sup>, Janette J. Tazmi-Staal<sup>7</sup>, Eva G. Willems<sup>7</sup>, Roxane Heller<sup>8</sup>, Shai A. Gajadin<sup>9</sup>, Wouter J.B. Blox<sup>10</sup>, Laurien Oswald<sup>11</sup>, Sieshem Bindraban<sup>11</sup>, Rob Slingerland<sup>12</sup>, Herbert J. van de Sande<sup>13</sup>, Ronald N. van Rossem<sup>14</sup>, Stephanie van Loon-Kooij<sup>14</sup>, L. Martine Bek<sup>5</sup>, Julia C. Berentschot<sup>15</sup>, Merel E. Hellemons<sup>15</sup>, Susanne M. Huijts<sup>15</sup>, Joachim G.J.V. Aerts<sup>15</sup>, Majanka H. Heijenbrok-Kal<sup>5,6</sup>, Rita J.G. van den Berg-Emons<sup>5</sup>, Gerard M. Ribbers<sup>5,6</sup>

#### **ORCID IDs:**

0000-0001-5668-3435 Michel E. van Genderen

0000-0001-8408-0500 Jasper van Bommel

0000-0001-6808-7702 Diederik A.M.P.J. Gommers

0000-0003-1257-3108 Erwin Ista

0000-0001-9809-7311 Rutger Osterthun

0000-0003-1472-7158 Eva G. Willems

0000-0003-2706-0639 Laurien Oswald

0000-0001-8257-7070 L. Martine Bek

0000-0002-6666-5027 Merel E. Hellemons

0000-0002-6652-6254 Susanne M. Huijts

0000-0001-6662-2951 Joachim G.J.V. Aerts

0000-0002-2982-4404 Majanka H. Heijenbrok-Kal

0000-0001-6433-3398 Rita J.G. van den Berg-Emons

0000-0002-6114-349X Gerard M. Ribbers

#### **Author details**

<sup>1</sup>Department of Adult Intensive Care Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

<sup>2</sup>Departments of Pediatrics and Pediatric Surgery, Intensive Care Unit, Erasmus MC Sophia Children's Hospital Rotterdam, The Netherlands.

<sup>3</sup>Department of Internal Medicine, section Nursing Science, Erasmus MC, Erasmus University Medical Center Rotterdam, The Netherlands.

<sup>4</sup>Department of Physical Therapy, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

<sup>5</sup>Department of Rehabilitation Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

<sup>6</sup>Rijndam Rehabilitation, Rotterdam, The Netherlands.

<sup>7</sup>Laurens Intermezzo, Rotterdam, The Netherlands.

<sup>8</sup>Department of Respiratory Medicine, Ikazia Hospital, Rotterdam, The Netherlands.

<sup>9</sup>Department of Respiratory Medicine, IJsselland Hospital, Capelle aan de IJssel, The Netherlands.

<sup>10</sup>Department of Respiratory Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.


<sup>11</sup>Department of Respiratory Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.




<sup>12</sup>Department of Respiratory Medicine, Maasstad Hospital, Rotterdam, The Netherlands.

<sup>13</sup>Aafje Nursing Home, Rotterdam, The Netherlands.

<sup>14</sup>Department of Respiratory Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands.


<sup>15</sup>Department of Respiratory Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.








### A. Overall Population



### B. Males



### C. Females

